PET CT image of the Neck showing CA nasopharynx or carcinoma of nasopharynx from PET CT scannner.

PET CT image of the Neck showing CA nasopharynx or carcinoma of nasopharynx from PET CT scannner. Getty Images


January 11, 2022 — Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China. 

Clario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug efficacy evaluation. PET imaging has supported novel studies for Alzheimer's disease (AD) and other neurodegenerative diseases. A dedicated team of neuroscientists and project managers have led multiple trials in China to date. 

The new expanded offering leverages the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China, including amyloid, tau, and other targets.   

“Broadening our scope of clinical trials to further support drug development in neuroscience presents a unique opportunity for both patients and clinical researchers,” said Joyce Suhy, PhD, SVP Medical Imaging at Clario. “Our continued partnership with XingImaging is advancing therapeutics in APAC.” 

"XingImaging is proud to be working with Clario in providing PET imaging multi-center clinical trials,” said Gilles Tamagnan, CEO XingImaging, LLC. “Our partnership enables patients in China to participate in clinical trials testing novel neurodegenerative disease therapeutics." 

For more information: www.clario.com


Related Content

News | PACS

February 22, 2024 — aycan, a recognized leader in medical imaging, announced that Enspectra Health used aycan’s PACS ...

Time February 22, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Digital Pathology

January 26, 2024 — New research funded by the National Institute for Health and Care Research (NIHR) has led to the UK ...

Time January 26, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
Subscribe Now